NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free RYTM Stock Alerts $37.96 -1.21 (-3.09%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$37.23▼$39.4550-Day Range$37.96▼$43.8852-Week Range$15.50▼$52.57Volume750,715 shsAverage Volume567,333 shsMarket Capitalization$2.31 billionP/E RatioN/ADividend YieldN/APrice Target$54.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside43.1% Upside$54.33 Price TargetShort InterestBearish17.37% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.22Based on 6 Articles This WeekInsider TradingSelling Shares$3.92 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.44) to ($2.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 starsMedical Sector335th out of 921 stocksPharmaceutical Preparations Industry144th out of 418 stocks 3.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.37% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 3.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 1.2 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,924,525.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.44) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 37.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesMay 14, 2024 | insidertrades.comJoseph Shulman Sells 3,984 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockMay 15, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM)May 14, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 3,984 Shares of StockMay 12, 2024 | americanbankingnews.comBank of America Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) to NeutralMay 11, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $54.33 Average Price Target from AnalystsMay 9, 2024 | msn.comMario Lemieux Foundation presents AHN with $5 million gift to establish Mario Lemieux Center for Heart Rhythm CareMay 9, 2024 | msn.comLeon Talks Transformative Portrayal of Blues Legend Eddie Taylor in ‘The Rhythm and the Blues’ | EUR ExclusiveMay 9, 2024 | msn.comB of A Securities Downgrades Rhythm Pharmaceuticals (RYTM)May 9, 2024 | americanbankingnews.comNeedham & Company LLC Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $46.00May 8, 2024 | msn.comSpin Rhythm XD - Official VR & PlayStation Launch TrailerMay 8, 2024 | markets.businessinsider.comSteady Performance and Promising European Growth Justify Buy Rating for Rhythm PharmaceuticalsMay 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming CatalystsMay 8, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comRhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...May 8, 2024 | finance.yahoo.comQ1 2024 Rhythm Pharmaceuticals Inc Earnings CallMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Rhythm Pharmaceuticals’ Growth and Clinical Advancements Fuel OptimismMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rhythm Pharmaceuticals Amid Positive Prescription Growth and Pipeline PotentialMay 7, 2024 | msn.comRYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | investorplace.comThe 3 Best Nasdaq Stocks to Buy in May 2024May 7, 2024 | msn.comMarvelle Healthcare Revolutionizes Hydration with the Debut of Premium Natural Mineral Water Brand, RhythmMay 7, 2024 | msn.comRhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93MMay 7, 2024 | finance.yahoo.comRhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst ChallengesMay 7, 2024 | globenewswire.comRhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateMay 6, 2024 | finance.yahoo.comRhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual MeetingMay 3, 2024 | msn.comAnMed Rhythm on the River in Powdersville postponed: Here's what you need to knowSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/18/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees226Year FoundedN/APrice Target and Rating Average Stock Price Target$54.33 High Stock Price Target$79.00 Low Stock Price Target$42.00 Potential Upside/Downside+43.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-297.91% Pretax Margin-296.99% Return on Equity-179.26% Return on Assets-87.25% Debt Debt-to-Equity RatioN/A Current Ratio4.35 Quick Ratio4.20 Sales & Book Value Annual Sales$77.43 million Price / Sales29.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book37.58Miscellaneous Outstanding Shares60,970,000Free Float58,107,000Market Cap$2.31 billion OptionableOptionable Beta1.94 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.35MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $757.32kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $677.27kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $936.91kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $727.14kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief Human Resources Officer More ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNACADIA PharmaceuticalsNASDAQ:ACADJanux TherapeuticsNASDAQ:JANXIndiviorNASDAQ:INDVPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsCastleark Management LLCBought 63,900 shares on 5/17/2024Ownership: 0.105%Comerica BankSold 933 shares on 5/17/2024Ownership: 0.054%Janus Henderson Group PLCSold 465 shares on 5/16/2024Ownership: 1.019%California State Teachers Retirement SystemSold 1,103 shares on 5/16/2024Ownership: 0.079%Bayesian Capital Management LPBought 15,355 shares on 5/16/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 6 brokerages have issued twelve-month target prices for Rhythm Pharmaceuticals' shares. Their RYTM share price targets range from $42.00 to $79.00. On average, they expect the company's stock price to reach $54.33 in the next year. This suggests a possible upside of 43.1% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2024? Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of 2024. Since then, RYTM stock has decreased by 17.4% and is now trading at $37.96. View the best growth stocks for 2024 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings results on Tuesday, May, 7th. The company reported ($2.35) EPS for the quarter, missing analysts' consensus estimates of ($2.34) by $0.01. The business earned $26 million during the quarter, compared to the consensus estimate of $26.90 million. Rhythm Pharmaceuticals had a negative net margin of 297.91% and a negative trailing twelve-month return on equity of 179.26%. The firm's revenue for the quarter was up 126.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.92) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), BlackRock Future Health ETF (BMED), SPDR S&P Biotech ETF (XBI), Harbor Corporate Culture Small Cap ETF (HAPS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.42%), Healthcare of Ontario Pension Plan Trust Fund (1.20%), Janus Henderson Group PLC (1.02%), Canada Pension Plan Investment Board (0.95%), Price T Rowe Associates Inc. MD (0.79%) and National Bank of Canada FI (0.60%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.